US29772L1089
US29772L1089
Eton Pharmaceuticals, Inc.
Loading chart...
Financials
Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
| Breakdown | 2025 | 2024 | Change % |
|---|---|---|---|
| Total Revenue | 79.950.000 | 39.011.000 | 104.9% |
| Cost of Revenue | 37.210.000 | 15.600.000 | 138.5% |
| Gross Profit | 42.740.000 | 23.411.000 | 82.6% |
| 43.584.000 | 26.008.000 | 67.6% | |
| Operating Income | -844.000 | -2.597.000 | 67.5% |
| Pretax Income | -4.558.000 | -3.808.000 | 19.7% |
| Net Income Common Stockholders | -4.601.000 | -3.823.000 | 20.4% |
| -- | -- | -- | |
| -- | -- | -- |